Cargando…
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
BACKGROUND: Despite widespread searches, there are currently no validated biofluid markers for the detection of subclinical neuroinflammation in multiple sclerosis (MS). The dynamic nature of human metabolism in response to changes in homeostasis, as measured by metabolomics, may allow early identif...
Autores principales: | Yeo, Tianrong, Bayuangga, Halwan, Augusto-Oliveira, Marcus, Sealey, Megan, Claridge, Timothy D. W., Tanner, Rachel, Leppert, David, Palace, Jacqueline, Kuhle, Jens, Probert, Fay, Anthony, Daniel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549622/ https://www.ncbi.nlm.nih.gov/pubmed/36210459 http://dx.doi.org/10.1186/s12974-022-02614-8 |
Ejemplares similares
-
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
por: Probert, Fay, et al.
Publicado: (2021) -
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
por: Yeo, Tianrong, et al.
Publicado: (2021) -
Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands
por: Probert, Fay, et al.
Publicado: (2022) -
Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
por: Probert, Fay, et al.
Publicado: (2022) -
Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
por: Yeo, Tianrong, et al.
Publicado: (2019)